AstraZeneca and Pfizer vaccines are effective against the delta variant, studies
LONDON (Reuters) – Vaccines made by Pfizer and AstraZeneca offer more than 90 percent protection against hospitalization risks for people with delta-type coronavirus, an analysis released on Monday by Public Health England said.
The publication of this study coincides with the announcement by the British Prime Minister, Boris Johnson, that the last stage of dismantling in England will be postponed to July 19, which was tentatively scheduled for June 21, given the particularly high pollution figures. This variant was first identified in India.
According to PHE, the COVID-19 vaccine from Pfizer/Biontech is 96% effective in preventing hospitalization for a person with the delta variant, a level just above the 92% protection evaluated for the AstraZeneca and Oxford University product.
PHE indicates that these levels of protection are highly comparable to those observed for the Alpha variant, which was identified for its part in Kent.
(Alistair Smoot, French version by Nicolas Delam, edited by Marc Angrand)
“Unapologetic pop culture trailblazer. Freelance troublemaker. Food guru. Alcohol fanatic. Gamer. Explorer. Thinker.”